Signos is a Continuous Glucose & Metabolic company founded in 2018 and based in San Jose, United States. It has raised $40M in total funding, most recently a Growth in 2026.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| May 27, 2026 | Growth | $20M | — | — |
| Oct 24, 2023 | Series B | $20M | — | Cheyenne Ventures, GV |
The Signos Glucose Monitoring System pairs a continuous glucose monitor with an AI-enhanced app that delivers real-time, personalized recommendations to help users lose weight and sustain it. The app interprets glucose responses to food, activity, and timing, then nudges users toward better choices around eating and exercise. Cleared by the FDA as the first over-the-counter CGM system designed for weight management, the platform integrates Dexcom's Stelo biosensor and is distributed through Dexcom's direct-to-consumer channel, extending CGM-driven metabolic insight to a mainstream, non-diabetic weight-loss audience.
No recently verified openings are available right now. The company's careers page has the latest.
View all careers ↗